Fidson Healthcare Plc reported a 41% increase in revenue for 2025, reaching N119.06 billion. The growth was primarily driven by a 41.5% rise in ethical drug sales, which contributed N77.8 billion to the total revenue. The company attributed the surge to expanded market reach and improved product distribution across key regions. No breakdown of regional performance or specific product lines was disclosed in the initial release. The financial results reflect continued demand for prescription medicines in Nigeria's pharmaceutical sector.
Fidson's N77.8 billion from ethical drugs suggests a growing reliance on prescription medications in Nigerian households. With over two-thirds of its revenue now tied to ethical sales, the company is positioning itself as a dominant player in a sector often overshadowed by cheaper generics. This shift may signal stronger regulatory compliance and brand trust, but also raises concerns about affordability for low-income patients. If this trend continues, it could reshape how Nigerians access essential medicines.
